All In Biotech

Drug Trial Radar · NCT07782476

Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis

A Phase I/II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

67

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Oct 2027

Study completion Jan 2028

Sponsor

Sponsor type
Industry
First posted
Aug 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I/II, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN6005 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD). The study consists of three parts: Part A (single ascending dose in healthy participants), Part B (multiple ascending dose in AD patients), and Part C (multiple-dose efficacy and safety assessment in AD patients). The primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HXN6005.

Conditions

  • Health Adult Subjects
  • Atopic Dermatitis (AD)

Interventions

  • HXN6005Drug

    Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive a single subcutaneous dose of HXN6005.

  • PlaceboDrug

    Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive a single subcutaneous dose of placebo.

  • HXN6005Drug

    Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of HXN6005.

  • PlaceboDrug

    Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of placebo.

  • HXN6005Drug

    Participants will be enrolled in parallel into one of two dose cohorts and will receive multiple subcutaneous doses of HXN6005.

  • PlaceboDrug

    Participants will be enrolled in a single cohort and will receive multiple subcutaneous doses of placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A Adverse eventsTime frame: Up to day 141
  2. Part B Adverse EventsTime frame: Up to day 197
  3. Part C EfficacyTime frame: Up to day 113

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.